DMP1-mediated transformation of DPSCs to CD31<sup>+</sup>/CD144<sup>+</sup> cells demonstrate endothelial phenotype both <i>in vitro</i> and <i>in vivo</i>
Ganapathy A., Chen Y., Bakthavachalam V., George A.
Animal Study, published in Front Cell Dev Biol (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Front Cell Dev Biol (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40861275
- PMCID
- PMC12371194
- DOI
- 10.3389/fcell.2025.1630129
- Citations
- 1
Abstract (original English)
Introduction Dental pulp stem cells (DPSCs), can differentiate into endothelial cells (ECs), offering a promising strategy for generation of new blood vessels which is crucial for tissue repair and regeneration. Many studies have focused on optimizing conditions for differentiating DPSCs into ECs in vitro and subsequent validation of the vasculogenic potential of newly generated ECs in vivo . Previously, we demonstrated the ability of the HUVEC ECM scaffold along with DMP1 stimulation would drive endothelial-specific lineage of DPSCs. Methods In this study, DMP1-treated DPSCs were cultured on HUVEC ECM for 7 days and sorted using angiogenic-specific markers CD31 and CD144. The cells were separated into a positive fraction (CD31 + /CD144 + ) and a negative fraction (CD31 - /CD144 - ). To assess if ECs transformed from DMP1 stimulated DPSCs maintain their endothelial properties over time, we cultured both the positive CD31 + /CD144 + and negative CD31 - /CD144 - fractions along with unstimulated DPSCs and assessed their angiogenic characteristics by gene expression analysis, functional properties using a tubule formation assay and in vivo subcutaneous implantation model. Results and discussion The findings of this study indicate that the CD31 + /CD144 + fraction, retains both the phenotypic and functional characteristics of ECs, in contrast to the CD31 - /CD144 - fraction. Furthe
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.